Fortrea A.I CyberSecurity Scoring
12/09/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Fortrea in 2026.
No incidents recorded for Fortrea in 2026.
No incidents recorded for Fortrea in 2026.
Biotechnology Research
Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.
CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Latest updates, reports, and threat intel affecting the global network.
Stop defending the network Discover how Liveness Detection, Micro-Segmentation, and Quantum-Resistant Crypto are defining 2026...
RSAC 2026 CONFERENCE – San Francisco – Artificial intelligence has been hailed by many as a game changer for cybersecurity,...
By Andre Pienaar. The Trump Administration's Cyber Strategy for America signals a decisive shift — from reactive compliance to proactive...
Data governance is the structured, ongoing process of managing an organization's data to ensure its availability, usability, integrity,...
Groundbreaking Research from University of East Anglia Revolutionizes Medical Image Security for NHS In a pioneering development that...
As of today, March 3, 2026, the cybersecurity landscape has shifted from a focus on protecting the "perimeter" to a desperate race to secure...
SANTA CLARA, Calif. — In a move that fundamentally redraws the map of the cybersecurity industry, Palo Alto Networks (NASDAQ: PANW)...
Badger Fortress (formerly JSCM Group) provides comprehensive cybersecurity services, including managed detection and response, security...
BO Team, 3/3: Since January 2024, a shadowy cyber collective has attached itself to Ukraine's military intelligence.
A vulnerability was identified in Totolink A3002MU Hh-B20211125.1046. Affected is the function formWlEncrypt of the file /boafrm/formWlEncrypt. The manipulation of the argument submit-url leads to buffer overflow. It is possible to initiate the attack remotely. The exploit is publicly available and might be used.
A vulnerability was determined in Totolink A3002MU Hh-B20211125.1046. This impacts the function formWlAc of the file /boafrm/formWlAc. Executing a manipulation of the argument submit-url can lead to buffer overflow. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized.
A flaw was found in the OpenShift console. Unauthenticated access to the `/api/devfile/` and `/api/devfile/samples/` endpoints allows a remote attacker to send crafted devfile payloads. This can lead to Server-Side Request Forgery (SSRF), where the console pod makes requests to internal services and reflects partial responses to the attacker. Additionally, by sending repeated large requests without a specified content length, an attacker can cause unbounded memory growth, leading to a Denial of Service (DoS).
In Vinyl Cache before 9.0,2, workspace buffer overflow vulnerability was found in the .upper() and .lower() string type methods of VCL. This can be used as a remote denial of service (DoS) vector to make the child process segfault or assert, and then restart. Effectively exploiting this vulnerability requires prior knowledge about the VCL in use and the ability to craft a request that contains a string that is long enough to fill the remaining workspace at the call site while staying under the different request size limits (http_req_size, http_req_hdr_len, etc.).
A vulnerability was found in Totolink A3002MU Hh-B20211125.1046. This affects the function formSchedule of the file /boafrm/formSchedule. Performing a manipulation of the argument webpage results in buffer overflow. The attack is possible to be carried out remotely. The exploit has been made public and could be used.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.